Advanced

Worse breast cancer prognosis in insulin treated diabetic patients - A population based registry study in Sweden

H., Olsson LU ; Einefors, R; P., Broberg LU and M.L., Olsson LU (2015) 37th San Antonio Breast Cancer Symposium In Cancer Research 75(9 Suppl).
Abstract
Background. Diabetes may be linked to incidence of different tumor diseases and prognosis through various mechanisms such as the disease itself, hyperglycemia, obesity and anti-diabetes therapy. Material and methods. The study includes all women with BC diagnosed in Sweden between 2000 through 2008 (n=54406). The women had no previous cancer diagnosis during the period of 1958-1999. Dates of birth, BC diagnosis and TNM-stage where directly extracted from the cancer registry. The women's anti-diabetes therapy was gathered from the Swedish Prescribed Drug Registry. Information regarding the cause of death and date of death was obtained from the Cause of Death Registry and tbe Swedish Population Register up until the 31st of December 2012 and... (More)
Background. Diabetes may be linked to incidence of different tumor diseases and prognosis through various mechanisms such as the disease itself, hyperglycemia, obesity and anti-diabetes therapy. Material and methods. The study includes all women with BC diagnosed in Sweden between 2000 through 2008 (n=54406). The women had no previous cancer diagnosis during the period of 1958-1999. Dates of birth, BC diagnosis and TNM-stage where directly extracted from the cancer registry. The women's anti-diabetes therapy was gathered from the Swedish Prescribed Drug Registry. Information regarding the cause of death and date of death was obtained from the Cause of Death Registry and tbe Swedish Population Register up until the 31st of December 2012 and 31st of December 2013 respectively. Analyses have been restricted to patients receiving insulin therapy (n=2463) and their breast cancer prognosis has been calculated in comparison with breast cancer patients without diabetes. All analyses were adjusted for TNM-stage and age at diagnosis. Results. Patients with insulin treated diabetes had a worse prognosis compared with other women with breast cancer (HR 1.7, 95%CI 1.5-2.0). The worse prognosis could be seen both for patients with ER+ and ER- tumors. The worst prognosis was seen for patients treated with NPH insulins (HR 2.8, 95% CI 2.4-3.3) while patients treated with long-acting insulin analogs had an intermediate prognosis (HR 1.6, 95% CI 1.2-2.2). Those women treated with NPH insulins and metformin had a slightly worse prognosis (HR 1.4, 95% CI 1.0-1.8). The results for breast cancer specific survival and total survival were similar. Conclusion. Our results imply that insulin treated breast cancer patients have a worse survival compared with other women with breast cancer regardless of tumor stage. Metformin therapy may partially counteract the association. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
insulin, insulin derivative, metformin, isophane insulin, long acting insulin, breast cancer, cancer prognosis, human, register, diabetic patient, population, Sweden, prognosis, female, diabetes mellitus, patient, therapy, neoplasm, cancer staging, cancer patient, survival, cause of death, diagnosis, obesity, cancer specific survival, hyperglycemia, insulin treatment, death, cancer registry, cancer diagnosis, diseases
in
Cancer Research
volume
75
issue
9 Suppl
publisher
American Association for Cancer Research Inc.
conference name
37th San Antonio Breast Cancer Symposium
conference location
San Antonio, Texas, United States
conference dates
2014-12-09 - 2014-12-13
ISSN
0008-5472
DOI
10.1158/1538-7445.SABCS14-P4-11-02
language
English
LU publication?
yes
id
3160e485-d851-4061-b76f-7709bf8f18d8
date added to LUP
2019-07-01 11:49:26
date last changed
2019-07-01 11:49:26
@misc{3160e485-d851-4061-b76f-7709bf8f18d8,
  abstract     = {Background. Diabetes may be linked to incidence of different tumor diseases and prognosis through various mechanisms such as the disease itself, hyperglycemia, obesity and anti-diabetes therapy. Material and methods. The study includes all women with BC diagnosed in Sweden between 2000 through 2008 (n=54406). The women had no previous cancer diagnosis during the period of 1958-1999. Dates of birth, BC diagnosis and TNM-stage where directly extracted from the cancer registry. The women's anti-diabetes therapy was gathered from the Swedish Prescribed Drug Registry. Information regarding the cause of death and date of death was obtained from the Cause of Death Registry and tbe Swedish Population Register up until the 31st of December 2012 and 31st of December 2013 respectively. Analyses have been restricted to patients receiving insulin therapy (n=2463) and their breast cancer prognosis has been calculated in comparison with breast cancer patients without diabetes. All analyses were adjusted for TNM-stage and age at diagnosis. Results. Patients with insulin treated diabetes had a worse prognosis compared with other women with breast cancer (HR 1.7, 95%CI 1.5-2.0). The worse prognosis could be seen both for patients with ER+ and ER- tumors. The worst prognosis was seen for patients treated with NPH insulins (HR 2.8, 95% CI 2.4-3.3) while patients treated with long-acting insulin analogs had an intermediate prognosis (HR 1.6, 95% CI 1.2-2.2). Those women treated with NPH insulins and metformin had a slightly worse prognosis (HR 1.4, 95% CI 1.0-1.8). The results for breast cancer specific survival and total survival were similar. Conclusion. Our results imply that insulin treated breast cancer patients have a worse survival compared with other women with breast cancer regardless of tumor stage. Metformin therapy may partially counteract the association.},
  articleno    = {Abstract P4-11-02},
  author       = {H., Olsson and Einefors, R and P., Broberg and M.L., Olsson},
  issn         = {0008-5472},
  keyword      = {insulin,insulin derivative,metformin,isophane insulin,long acting insulin,breast cancer,cancer prognosis,human,register,diabetic patient,population,Sweden,prognosis,female,diabetes mellitus,patient,therapy,neoplasm,cancer staging,cancer patient,survival,cause of death,diagnosis,obesity,cancer specific survival,hyperglycemia,insulin treatment,death,cancer registry,cancer diagnosis,diseases},
  language     = {eng},
  location     = {San Antonio, Texas, United States},
  note         = {Conference Abstract},
  number       = {9 Suppl},
  publisher    = {American Association for Cancer Research Inc.},
  series       = {Cancer Research},
  title        = {Worse breast cancer prognosis in insulin treated diabetic patients - A population based registry study in Sweden},
  url          = {http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-02},
  volume       = {75},
  year         = {2015},
}